This company seems to have been delisted
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Taro Pharmaceutical
TARO
HK$337.28
Share price
0.00%
Change (1 day)
8.72%
Change (1 year)
Categories
Revenue for Taro Pharmaceutical (TARO)
Revenue in 2023 (TTM): HK$4.78 Billion
According to Taro Pharmaceutical's latest financial reports the company's current revenue (TTM 
) is HK$4.79 Billion. an increase over the revenue in the year 2022 that were of HK$4.45 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Taro Pharmaceutical from 1996 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 | HK$4.77 B | 7.19% |
| 2022 | HK$4.45 B | 0.77% |
| 2021 | HK$4.41 B | -1.01% |
| 2020 | HK$4.46 B | -11.83% |
| 2019 | HK$5.06 B | -2.85% |
| 2018 | HK$5.20 B | -2.4% |
| 2017 | HK$5.33 B | -27.4% |
| 2016 | HK$7.35 B | 2.01% |
| 2015 | HK$7.20 B | 15.29% |
| 2014 | HK$6.25 B | 9.35% |
| 2013 | HK$5.71 B | 13.3% |
| 2012 | HK$5.04 B | 28.47% |
| 2011 | HK$3.92 B | 28.77% |
| 2010 | HK$3.05 B | 9.99% |
| 2009 | HK$2.77 B | |
| 2005 | HK$2.34 B | 6.08% |
| 2004 | HK$2.20 B | -9.7% |
| 2003 | HK$2.44 B | 48.19% |
| 2002 | HK$1.65 B | 40.94% |
| 2001 | HK$1.17 B | 44.61% |
| 2000 | HK$0.80 B | 24.37% |
| 1999 | HK$0.65 B | 25.96% |
| 1998 | HK$0.51 B | 9.14% |
| 1997 | HK$0.47 B | 8.35% |
| 1996 | HK$0.43 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | HK$490.28 B | 10,125.96% | 🇺🇸 USA |
 Merck MRK | HK$501.73 B | 10,364.81% | 🇺🇸 USA |
 Johnson & Johnson JNJ | HK$701.17 B | 14,524.58% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | HK$130.41 B | 2,620.08% | 🇮🇱 Israel |
 GlaxoSmithKline GSK | HK$318.57 B | 6,544.52% | 🇬🇧 UK |
 Novartis NVS | HK$417.75 B | 8,613.09% | 🇨🇭 Switzerland |